The Human Gene for Mannan-Binding Lectin-Associated Serine

Total Page:16

File Type:pdf, Size:1020Kb

The Human Gene for Mannan-Binding Lectin-Associated Serine Genes and Immunity (2001) 2, 119–127 2001 Nature Publishing Group All rights reserved 1466-4879/01 $15.00 www.nature.com/gene The human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2–3 C Stover1, Y Endo2, M Takahashi2, NJ Lynch1, C Constantinescu1, T Vorup-Jensen3, S Thiel3, H Friedl4, T Hankeln4, R Hall5, S Gregory5, T Fujita2 and W Schwaeble1 1Department of Microbiology and Immunology, University of Leicester, Leicester, UK; 2Department of Biochemistry, Fukushima Medical University, School of Medicine, Fukushima, Japan; 3Department of Medical Microbiology and Immunology, The Bartholin Building, University of Århus, Århus, Denmark; 4Genterprise, Institut fu¨r Molekulargenetik und Gentechnische Sicherheit, Johannes Gutenberg University Mainz, Mainz, Germany; 5The Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK The proteases of the lectin pathway of complement activation, MASP-1 and MASP-2, are encoded by two separate genes. The MASP1 gene is located on chromosome 3q27, the MASP2 gene on chromosome 1p36.23–31. The genes for the classical complement activation pathway proteases, C1r and C1s, are linked on chromosome 12p13. We have shown that the MASP2 gene encodes two gene products, the 76 kDa MASP-2 serine protease and a plasma protein of 19 kDa, termed MAp19 or sMAP. Both gene products are components of the lectin pathway activation complex. We present the complete primary structure of the human MASP2 gene and the tight cluster that this locus forms with non-complement genes. A comparison of the MASP2 gene with the previously characterised C1s gene revealed identical positions of introns separating orthologous coding sequences, underlining the hypothesis that the C1s and MASP2 genes arose by exon shuffling from one ancestral gene. Genes and Immunity (2001) 2, 119–127. Keywords: complement; lectin pathway; serine proteases; gene cluster; MASP2 gene Introduction vertase, C4b2b, and the C5 convertase, C4b2b(C3b)n. The alternative pathway forms an amplification loop of comp- The complement system is an integral part of the innate lement activation and is initiated by binding of the comp- antimicrobial immune defence and mediates humoral lement activation product C3b to Factor B. The sub- and cellular interactions within the immune response, sequent cleavage of Factor B by Factor D forms an including chemotaxis, phagocytosis, cell adhesion, and B enzymatically active complex, C3bBb, which converts 1 cell differentiation. Complement may be activated via native C3 to C3b. Accumulation of multiple C3b mol- three different routes, the classical pathway, the alterna- ecules in proximity of the alternative pathway convertase tive pathway, and the recently described lectin pathway. C3bBb allows the complex to cleave and activate the fifth The classical activation pathway is initiated by binding of component of complement, C5. the hexaoligomeric recognition molecule C1q to immune The lectin pathway can be activated in the absence of complexes via its globular heads. This effects a confor- immune complexes and is initiated by the recognition of mational change of its collagenous stalks which in turn carbohydrate structures present on microbial organisms leads to the activation of the C1q-associated serine pro- via macromolecular complexes present in body fluids. tease complexes C1r2 and C1s2. Of these, C1r cleaves and These complexes are composed of a multivalent pattern activates the zymogen C1s. Activated C1s subsequently recognition subunit and associated serine proteases cleaves C4 and C4b bound C2 to generate the C3 con- which initiate complement activation upon binding of the recognition subunits to microbial oligosaccharide struc- tures. To date, two pattern recognition components of the Correspondence: Dr WJ Schwaeble, Department of Microbiology and Immunology, University of Leicester, University Road, Leicester LE1 lectin activation pathway have been described, the well 9HN, UK. E-mail: ws5Ȱle.ac.uk characterised plasma glycoprotein mannan-binding lectin This work was supported by the Wellcome Trust, the German (MBL)2 and ficolin p35,3 both members of the collectin Research Foundation (Deutsche Forschungsgemeinschaft), the family,4,5 yet differing in their binding specificities to Japanese Society for the Promotion of Science, and the EMDO microbial surface oligosaccharides. As these vary con- Foundation, Switzerland. siderably amongst members of the collectin family, the Sequence data from this article have been deposited with the EMBL/GenBank Data Libraries under accession numbers presence of more than one recognition subunit may result AL109811, AB033742, AJ297949, AJ299718, and AJ300188. in a wider spectrum of microbial surfaces recognised by Received 4 December 2000; accepted 1 February 2001 the lectin pathway activation complexes. MBL forms a Organisation of the human MASP2 gene locus C Stover et al 120 hexoidal macromolecular complex of six structural sub- sequence coding for the signal peptide is split by an units each composed of three identical polypeptide intron of 83 bp (Figure 1a). Exon b codes for the remain- chains. This associates with two distinct serine proteases, der of the signal peptide (R)LLTLLGLLCGSVA and the the MBL-associated serine proteases-1 and -2 (ie, MASP- N-terminal 63 residues of the CUB I domain. The C-ter- 1, MASP-2), and a 19 kDa MASP-2 related plasma pro- minal 59 residues of the CUB I domain are encoded by tein, termed MAp19 or sMAP.6 No detailed information exon c, separated from exon b by 157 bp and from exon is yet available on the stoichiometry of lectin pathway d, the single exon coding for the EGF-like domain, by activation complexes formed with ficolin p35. It is, how- 1016 bp. The alternative splice/polyadenylation exon e ever, clear that ficolin p35 complexes associate with (which contains coding sequence for the four C-terminal MASP-1, MASP-2 and MAp19/sMAP and initiate the lec- amino acids of MAp19 not found in MASP-2, namely glu- tin pathway via the aforementioned serine proteases.3 In tamic acid, glutamine, serine, and leucine, and sequence vitro, purified and recombinant MASP-2 was shown to of the 3Ј UT region specific for MAp19 mRNA) follows cleave the fourth and second component of complement after 454 bp of intronic sequence. The 3Ј boundary of (ie, C4 and C2) in absence of MASP-1.6–8 The sequential exon e is determined by the position of the poly(A) proteolytic cleavage of C4 and C4b bound C2 to form the addition site14 noted in the human MAp19 mRNA tran- C3 convertase, C4b2b, and the C5 convertase, scripts with the accession numbers Y18281–Y18284. 1262 C4b2b(C3b), respectively, is the essential step by which bp further downstream, sequence for the second CUB the lectin pathway activation complex as well as the structural domain is split by an intron of 316 bp (exon f, classical pathway activation complex initiate further 197 bp; exon g, 148 bp, respectively). An intron of 1997 downstream activation of complement.7,8 The potential of bp follows (AJ299718). The two CCP domains of MASP- MASP-2 to activate complement in absence of MASP-1 in 2 are encoded by two exons each over a stretch of 7.6 kb, vitro is supported by the analysis of sera of a recently exon h (119 bp) and exon i (79 bp), exon j (135 bp) and established MASP-1 deficient mouse strain, which exhib- exon k (75 bp), respectively. 2527 bp further downstream, its effective lectin pathway activation under physiological exon l encodes the serine protease domain of MASP-2 9 conditions. Thus, MASP-2 is the effector component of and contains the 3Ј UT region specific for MASP-2 the lectin pathway of complement activation. MASP-1 mRNA. The 3Ј boundary of exon l is determined from and MAp19 are constitutive components of the lectin the position of the poly (A) addition site14 found in cDNA pathway activation complexes, their specific functional clones Y09926, phl-1, phl-2, phl-3.15 Exons b-l are pre- role(s), however, have yet to be defined. ceded by polypyrimidine rich tracts. Sequence compari- We have previously shown that a single structural son of the clones aligned in Figure 1 revealed only two MASP2 gene of approximately 20 kb on chromosome variants (transitions) within the coding sequence of the 1p36.23–31 is transcribed and processed to generate two MASP2 gene: the codon for the amino acid position 362 gene products, a 2.6 kb MASP-2 mRNA, encoding the 76 of the mature MASP-2 protein is GTG (valine) in kDa MASP-2 serine protease, or an abundant 1.0 kb AL109811 and GCG (alanine) in AJ300188, respectively; mRNA transcript, encoding a truncated MASP-2 related the codon for amino acid position 478 is TCC (serine) in plasma protein of 19 kDa devoid of a serine protease AL109811 and TCT (serine) in AJ300188, respectively. domain, termed MAp19 or sMAP.10–13 The codon phases (positions of introns within the The present report amends and completes our pre- codon) are given in Table 1. They are identical for the viously presented organisational map (based solely on human MASP2, MASP1, and C1s genes in the ortholog- genomic PCR)10,11 by a comparative analysis of overlap- ous exonic composition represented in MASP2 exons a, ping sequences obtained from human genomic DNA iso- 16 Ј lated as independent YAC, BAC and ␭FixII clones. These b, c, d, f, g, h, i, j, and k. The codon phase at the 5 end of exon l is also identical for the orthologous position in represent approximately 222 kb of the chromosomal area 17 1p36.2–3. Furthermore, we present putative promoter the human C1r gene. A GC level of 50.37% was determined for sequence elements responsible for the strict hepatic expression pat- − tern of MASP-2 and MAp19 mRNA.
Recommended publications
  • MASP-1, a Promiscuous Complement Protease: Structure of Its Catalytic Region Reveals the Basis of Its Broad Specificity 1
    MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity 1 József Dobó 2,3* , Veronika Harmat 3† , László Beinrohr *, Edina Sebestyén *, Péter Závodszky *, Péter Gál 2* * Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences, Karolina út 29, H-1113, Budapest, Hungary † Protein Modeling Group, Hungarian Academy of Sciences, and Laboratory of Structural Chemistry and Biology, Institute of Chemistry, Eötvös Loránd University , Pázmány Péter sétány 1A, H-1117, Budapest, Hungary Running title: Structure of MASP-1 CCP1-CCP2-SP Keywords (not in the title): lectin pathway; innate immunity; modular serine protease; mannan-binding lectin; MBL-associated serine protease; MASP-2; C1r; C1s; thrombin; trypsin; factor D 1 Abstract Mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1) is an abundant component of the lectin pathway of complement. The related enzyme, MASP-2 is capable of activating the complement cascade alone. Though the concentration of MASP-1 far exceeds that of MASP-2 only a supporting role of MASP-1 has been identified regarding lectin pathway activation. Several non-complement substrates, like fibrinogen and factor XIII, have also been reported. MASP-1 belongs to the C1r/C1s/MASP family of modular serine proteases, however its serine protease domain is evolutionary different. We have determined the crystal structure of the catalytic region of active MASP-1 and refined it to 2.55 Å resolution. Unusual features of the structure are: an internal salt bridge (similar to one in factor D) between the S1 Asp189 and Arg224, and a very long 60-loop.
    [Show full text]
  • The Membrane Complement Regulatory Protein CD59 and Its Association with Rheumatoid Arthritis and Systemic Lupus Erythematosus
    Current Medicine Research and Practice 9 (2019) 182e188 Contents lists available at ScienceDirect Current Medicine Research and Practice journal homepage: www.elsevier.com/locate/cmrp Review Article The membrane complement regulatory protein CD59 and its association with rheumatoid arthritis and systemic lupus erythematosus * Nibhriti Das a, Devyani Anand a, Bintili Biswas b, Deepa Kumari c, Monika Gandhi c, a Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India b Department of Zoology, Ramjas College, University of Delhi, India c University School of Biotechnology, Guru Gobind Singh Indraprastha University, India article info abstract Article history: The complement cascade consisting of about 50 soluble and cell surface proteins is activated in auto- Received 8 May 2019 immune inflammatory disorders. This contributes to the pathological manifestations in these diseases. In Accepted 30 July 2019 normal health, the soluble and membrane complement regulatory proteins protect the host against Available online 5 August 2019 complement-mediated self-tissue injury by controlling the extent of complement activation within the desired limits for the host's benefit. CD59 is a membrane complement regulatory protein that inhibits the Keywords: formation of the terminal complement complex or membrane attack complex (C5b6789n) which is CD59 generated on complement activation by any of the three pathways, namely, the classical, alternative, and RA SLE the mannose-binding lectin pathway. Animal experiments and human studies have suggested impor- Pathophysiology tance of membrane complement proteins including CD59 in the pathophysiology of rheumatoid arthritis Disease marker (RA) and systemic lupus erythematosus (SLE). Here is a brief review on CD59 and its distribution, structure, functions, and association with RA and SLE starting with a brief introduction on the com- plement system, its activation, the biological functions, and relations of membrane complement regu- latory proteins, especially CD59, with RA and SLE.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Properdin Factor D: Effects on Thrombin-Induced Platelet Aggregation
    Properdin factor D: effects on thrombin-induced platelet aggregation. A E Davis 3rd, D M Kenney J Clin Invest. 1979;64(3):721-728. https://doi.org/10.1172/JCI109515. Research Article Factor D, when preincubated with platelet suspensions, at concentrations as low as 1.2 micrograms/ml, inhibited thrombin-induced platelet aggregation. No inhibition of collagen or arachidonic acid-induced platelet aggregation was found. Inhibition occurred, but to a lesser extent, when thrombin and factor D were added to platelets at the same time. No inhibition occurred when factor D was added after thrombin. Thrombin was able to overcome inhibition by factor D by increasing its concentration. Diisopropyl-phosphorofluoridate-inactivated factor D also inhibited thrombin-induced platelet aggregation so that enzymatic activity of factor D was not required for inhibition. Factor D absorbed with hirudin coupled to Sepharose 6B showed no decrease in inhibitory capacity. 125I-Factor D bound to platelets in a manner suggesting an equilibrium reaction similar to thrombin. At low factor D input, binding was linear, whereas at higher input, binding began to approach saturation. Binding of 125I-labeled thrombin to platelets was inhibited by factor D. Analysis of these data show that factor D does not alter the total number of thrombin molecules which bind to the platelet surface at saturation. However, the dissociation constant for thrombin is altered from 2.78 to 6.90 nM in the presence of factor D (20 micrograms/ml). Factor D is thus a competitive inhibitor of thrombin binding, although the affinity of factor D for the platelet thrombin receptor is much less […] Find the latest version: https://jci.me/109515/pdf Properdin Factor D EFFECTS ON THROMBIN-INDUCED PLATELET AGGREGATION ALVIN E.
    [Show full text]
  • An Anticomplement Agent That Homes to the Damaged Brain and Promotes Recovery After Traumatic Brain Injury in Mice
    An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice Marieta M. Rusevaa,1,2, Valeria Ramagliab,1, B. Paul Morgana, and Claire L. Harrisa,3 aInstitute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom; and bDepartment of Genome Analysis, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands Edited by Douglas T. Fearon, Cornell University, Cambridge, United Kingdom, and approved September 29, 2015 (received for review July 15, 2015) Activation of complement is a key determinant of neuropathology to rapidly and specifically inhibit MAC at sites of complement and disability after traumatic brain injury (TBI), and inhibition is activation, and test its therapeutic potential in experimental TBI. neuroprotective. However, systemic complement is essential to The construct, termed CD59-2a-CRIg, comprises CD59a linked fight infections, a critical complication of TBI. We describe a to CRIg via the murine IgG2a hinge. CD59a prevents assembly targeted complement inhibitor, comprising complement receptor of MAC in cell membranes (16), whereas CRIg binds C3b/iC3b of the Ig superfamily (CRIg) fused with complement regulator CD59a, deposited at sites of complement activation (17). The IgG2a designed to inhibit membrane attack complex (MAC) assembly at hinge promotes dimerization to increase ligand avidity. CD59- sites of C3b/iC3b deposition. CRIg and CD59a were linked via the 2a-CRIg protected in the TBI model, demonstrating that site- IgG2a hinge, yielding CD59-2a-CRIg dimer with increased iC3b/C3b targeted anti-MAC therapeutics may be effective in prevention binding avidity and MAC inhibitory activity. CD59-2a-CRIg inhibited of secondary neuropathology and improve neurologic recovery MAC formation and prevented complement-mediated lysis in vitro.
    [Show full text]
  • By Map44 Pathway Activation in a Manner Inhibitable Pattern
    Co-Complexes of MASP-1 and MASP-2 Associated with the Soluble Pattern-Recognition Molecules Drive Lectin Pathway Activation in a Manner Inhibitable This information is current as by MAp44 of September 28, 2021. Søren E. Degn, Lisbeth Jensen, Tomasz Olszowski, Jens C. Jensenius and Steffen Thiel J Immunol 2013; 191:1334-1345; Prepublished online 19 June 2013; Downloaded from doi: 10.4049/jimmunol.1300780 http://www.jimmunol.org/content/191/3/1334 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/06/19/jimmunol.130078 Material 0.DC1 References This article cites 43 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/191/3/1334.full#ref-list-1 Why The JI? Submit online. by guest on September 28, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Co-Complexes of MASP-1 and MASP-2 Associated with the Soluble Pattern-Recognition Molecules Drive Lectin Pathway Activation in a Manner Inhibitable by MAp44 Søren E.
    [Show full text]
  • Are Complement Deficiencies Really Rare?
    G Model MIMM-4432; No. of Pages 8 ARTICLE IN PRESS Molecular Immunology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Molecular Immunology j ournal homepage: www.elsevier.com/locate/molimm Review Are complement deficiencies really rare? Overview on prevalence, ଝ clinical importance and modern diagnostic approach a,∗ b Anete Sevciovic Grumach , Michael Kirschfink a Faculty of Medicine ABC, Santo Andre, SP, Brazil b Institute of Immunology, University of Heidelberg, Heidelberg, Germany a r a t b i c s t l e i n f o r a c t Article history: Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) accord- Received 29 May 2014 ing to national and supranational registries. They are still considered rare and even of less clinical Received in revised form 18 June 2014 importance. This not only reflects (as in all PIDs) a great lack of awareness among clinicians and gen- Accepted 23 June 2014 eral practitioners but is also due to the fact that only few centers worldwide provide a comprehensive Available online xxx laboratory complement analysis. To enable early identification, our aim is to present warning signs for complement deficiencies and recommendations for diagnostic approach. The genetic deficiency of any Keywords: early component of the classical pathway (C1q, C1r/s, C2, C4) is often associated with autoimmune dis- Complement deficiencies eases whereas individuals, deficient of properdin or of the terminal pathway components (C5 to C9), are Warning signs Prevalence highly susceptible to meningococcal disease. Deficiency of C1 Inhibitor (hereditary angioedema, HAE) Meningitis results in episodic angioedema, which in a considerable number of patients with identical symptoms Infections also occurs in factor XII mutations.
    [Show full text]
  • Complement Herbert L
    Host Defense 2011 Complement Herbert L. Mathews, Ph.D. COMPLEMENT Date: 4/11/11 Reading Assignment: Janeway’s Immunobiology, 7th Edition, pp. 54-55, 61-82, 406- 409, 514-515. Figures: (Unless otherwise noted) Janeway’s Immunobiology, 7th Edition, Murphy et al., Garland Publishing. KEY CONCEPTS AND LEARNING OBJECTIVES You will be able to describe the mechanism and consequences of the activation of the complement system. To attain the goals for these lectures you will be able to: a. List the components of the complement system. b. Describe the three activation pathways for complement. c. Explain the consequences of complement activation. d. Describe the consequence of complement deficiency. Page 1 Host Defense 2011 Complement Herbert L. Mathews, Ph.D. CONTENT SUMMARY Introduction Nomenclature Activation of Complement The classical pathway The mannan-binding lectin pathway The alternative pathway Biological Consequence of Complement Activation Cell lysis and viral neutralization Opsonization Clearance of Immune Complexes Inflammation Regulation of Complement Activation Human Complement Component Deficiencies Page 2 Host Defense 2011 Complement Herbert L. Mathews, Ph.D. Introduction The complement system is a group of more than 30 plasma and membrane proteins that play a critical role in host defense. When activated, complement components interact in a highly regulated fashion to generate products that: Recruit inflammatory cells (promoting inflammation). Opsonize microbial pathogens and immune complexes (facilitating antigen clearance). Kill microbial pathogens (via a lytic mechanism known as the membrane attack complex). Generate an inflammatory response. Complement activation takes place on antigenic surfaces. However, the activation of complement generates several soluble fragments that have important biologic activity.
    [Show full text]
  • C1q Binding to Surface-Bound Igg Is Stabilized by C1r2s2 Proteases
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.08.430229; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases Seline A. Zwarthoff1, Kevin Widmer2, Annemarie Kuipers1, Jürgen Strasser3, Maartje Ruyken1, Piet C. Aerts1, Carla J.C. de Haas1, Deniz Ugurlar4, Gestur Vidarsson5, Jos A. G. Van Strijp1, Piet Gros4, Paul W.H.I. Parren6,7, Kok P.M. van Kessel1, Johannes Preiner3, Frank J. Beurskens8, Janine Schuurman8, Daniel Ricklin2, Suzan H.M. Rooijakkers1 1Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; 2Pharmaceutical Sciences, University of Basel, Basel, Switzerland; 3University of Applied Sciences Upper Austria, 4020 Linz, Austria; 4Crystal and Structural Chemistry, Utrecht University, Utrecht, The Netherlands; 5Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands 6Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands. 7Lava Therapeutics, Utrecht, The Netherlands 8Genmab, Utrecht, The Netherlands; Running title: C1r2s2 enhance stability of C1q-IgG bioRxiv preprint doi: https://doi.org/10.1101/2021.02.08.430229; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Complement is an important effector mechanism for antibody-mediated clearance of infections and tumor cells. Upon binding to target cells, the antibody's constant (Fc) domain recruits complement component C1 to initiate a proteolytic cascade that generates lytic pores and stimulates phagocytosis.
    [Show full text]
  • Complement in Cancer: Untangling an Intricate Relationship
    REVIEWS Complement in cancer: untangling an intricate relationship Edimara S. Reis1*, Dimitrios C. Mastellos2*, Daniel Ricklin3, Alberto Mantovani4 and John D. Lambris1 Abstract | In tumour immunology, complement has traditionally been considered as an adjunctive component that enhances the cytolytic effects of antibody-based immunotherapies, such as rituximab. Remarkably, research in the past decade has uncovered novel molecular mechanisms linking imbalanced complement activation in the tumour microenvironment with inflammation and suppression of antitumour immune responses. These findings have prompted new interest in manipulating the complement system for cancer therapy. This Review summarizes our current understanding of complement-mediated effector functions in the tumour microenvironment, focusing on how complement activation can act as a negative or positive regulator of tumorigenesis. It also offers insight into clinical aspects, including the feasibility of using complement biomarkers for cancer diagnosis and the use of complement inhibitors during cancer treatment. An enormous body of data produced by converging indicated, however, that this versatile innate immune disciplines has provided unprecedented insight into the effector system mediates key homeostatic functions in intricate and dynamic relationship that exists between processes ranging from early vertebrate development developing tumours and the host immune system1–3. and tissue morphogenesis to tissue regeneration, cen­ It is widely accepted that neoplastic transformation
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Complement Activation in Factor D-Deficient Mice
    Complement activation in factor D-deficient mice Yuanyuan Xu*†, Minghe Ma‡, Gregory C. Ippolito*, Harry W. Schroeder, Jr.*, Michael C. Carroll‡, and John E. Volanakis*§ *Department of Medicine, University of Alabama, Birmingham, AL 35294; ‡Department of Pathology, Harvard Medical School, Boston, MA 02138; and §Biomedical Sciences Research Center ‘‘A. Fleming,’’ Vari 166 72, Greece Edited by Douglas T. Fearon, University of Cambridge, Cambridge, United Kingdom, and approved October 18, 2001 (received for review August 15, 2001) To assess the contribution of the alternative pathway in comple- mice. The results indicate that factor D is indispensable for ment activation and host defense and its possible role in the complement activation through the AP and that it plays a regulation of systemic energy balance in vivo, factor D-deficient significant role in opsonization of bacteria by ‘‘natural’’ IgM mice were generated by gene targeting. The mutant mice have no antibody. It is also shown that factor D does not play a major role apparent abnormality in development and their body weights are in fat metabolism. Interestingly, the data revealed a unique mode similar to those of factor D-sufficient littermates. Complement of factor B activation, which provides valuable insights into the activation could not be initiated in the serum of deficient mice by mechanism of AP activation. the alternative pathway activators rabbit erythrocytes and zymo- san. Surprisingly, injection of cobra venom factor (CVF) caused a Materials and Methods profound and reproducible reduction in serum C3 levels, whereas, Generation of Factor D-Deficient Mice. A gene targeting vector, as expected, there was no C3 reduction in factor B-deficient mice Adn͞TK, was constructed (9) on the backbone of pBluescript treated similarly.
    [Show full text]